Immune cells injected into skin tumors show promise in early trial

NCT ID NCT07144384

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-phase trial tests whether injecting special immune cells (natural killer cells) directly into skin cancer tumors can safely kill cancer cells. The study compares two types of donor NK cells—standard ones and ones engineered to be more potent—in 40 patients with basal or squamous cell carcinoma. The main goal is to see if the cells enter the tumor and cause any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Natural killer (NK) cells (standard and TGF-beta-imprinted) injected directly into the tumor

What this could lead to

If it works, this could point toward a new way to treat common skin cancers without surgery, using the body's own immune cells.

What could go wrong

This is a very early (Phase 1) pilot study with only 40 people. It is designed mainly to check safety and immune activity, not to prove the treatment works. The cells may not shrink tumors or could cause side effects like inflammation or injection reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SKIN SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma nodular basal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States